Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers

Kinase Inhibitor ◽

Met Receptor ◽

Met Receptor Tyrosine Kinase ◽

Liver Cancers ◽

Inhibitor Treatment

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

Radiation Oncology ◽

10.1186/1748-717x-4-69 ◽

2009 ◽

Vol 4 (1) ◽

Cited By ~ 63

Author(s):

James W Welsh ◽

Daruka Mahadevan ◽

Ron Ellsworth ◽

Laurence Cooke ◽

David Bearss ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Glioblastoma Cells ◽

Met Receptor ◽

Met Receptor Tyrosine Kinase

S-(−)-Oleocanthal as a c-Met receptor tyrosine kinase inhibitor and its application to synergize targeted therapies and prevent breast cancer recurrence

Olives and Olive Oil in Health and Disease Prevention ◽

10.1016/b978-0-12-819528-4.00037-7 ◽

2021 ◽

pp. 681-691

Author(s):

Khalid A. El Sayed

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Targeted Therapies ◽

Kinase Inhibitor ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Met Receptor Tyrosine Kinase

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [ 99m Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide

Molecular Imaging ◽

10.2310/7290.2015.00023 ◽

2015 ◽

Vol 14 (9) ◽

pp. 7290.2015.00023 ◽

Cited By ~ 3

Author(s):

Elaine M. Jagoda ◽

Sibaprasad Bhattacharyya ◽

Joseph Kalen ◽

Lisa Riffle ◽

Avrum Leeder ◽

...

Keyword(s):

Tyrosine Kinase ◽

Mouse Models ◽

Kinase Inhibitor ◽

Met Receptor ◽

Met Receptor Tyrosine Kinase

Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment

Genes & Nutrition ◽

10.1007/s12263-011-0225-y ◽

2011 ◽

Vol 7 (1) ◽

pp. 63-74 ◽

Cited By ~ 13

Author(s):

Paul W. Sylvester

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Anticancer Effects ◽

Inhibitor Treatment

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

10.32388/jfobd7 ◽

2020 ◽

Author(s):

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth

Delayed Therapy with Receptor Tyrosine Kinase Inhibitor Nintedanib Diminished Chronic Rejection in a Murine Lung Transplant Model

10.1055/s-0041-1725623 ◽

2021 ◽

Author(s):

J. Mauer ◽

A. Kuckhahn ◽

J. Distler ◽

B. Spriewald ◽

M. Ramsperger-Gleixner ◽

...

Keyword(s):

Tyrosine Kinase ◽

Chronic Rejection ◽

Lung Transplant ◽

Kinase Inhibitor ◽

Murine Lung ◽

Transplant Model

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Glomerular Changes in Rats Administered ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor - Linking Ultrastructure to Mechanism

Microscopy and Microanalysis ◽

10.1017/s1431927609097566 ◽

2009 ◽

Vol 15 (S2) ◽

pp. 16-17

Author(s):

J Fagerland ◽

S Morgan

Keyword(s):

Tyrosine Kinase ◽

Receptor Tyrosine Kinase Inhibitor

Kinase Inhibitor ◽

Extended abstract of a paper presented at Microscopy and Microanalysis 2009 in Richmond, Virginia, USA, July 26 – July 30, 2009

The effect of combination treatment with gemcitabine and the EGFR-receptor tyrosine kinase inhibitor iressa with photodynamic therapy in bladder cancer

European Urology Supplements ◽

10.1016/s1569-9056(03)80175-6 ◽

2003 ◽

Vol 2 (1) ◽

pp. 44

Author(s):

C.H. Briggs ◽

C.D. Betts ◽

K.J. O'Flynn ◽

J.V. Moore ◽

N.W. Clarke

Keyword(s):

Bladder Cancer ◽

Photodynamic Therapy ◽

Tyrosine Kinase ◽

Combination Treatment ◽

Receptor Tyrosine Kinase Inhibitor

Kinase Inhibitor ◽

172 Preclinical profile of ABP309, a potent 2nd generation VEGF receptor tyrosine kinase inhibitor belonging to the class of aminonicotinamides

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)80180-0 ◽

2004 ◽

Vol 2 (8) ◽

pp. 54-55

Author(s):

J. Brueggen ◽

G. Bold ◽

R. Cozens ◽

P.W. Manley ◽

J. Mestan ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

2Nd Generation